^
    Back
    Association details:
    Biomarker:RET M918T
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:Cometriq (cabozantinib capsule) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Excerpt:
    In patients with RETM918T or RAS-mutant MTCs, cabozantinib offers significant PFS and OS advantages over wild-type MTCs.
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Cancer
    Title:

    Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

    Excerpt:
    These data suggest that cabozantinib provides the greatest clinical benefit to patients with MTC who have RET M918T or RAS mutations.
    DOI:
    10.1002/cncr.30252
    Trial ID:
    NCT00704730